Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ: ENVB )

1.740 -0.070 (-3.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,957,030
Open 1.730
Bid (Size) 1.700 (9)
Ask (Size) 1.750 (2)
Prev. Close 1.810
Today's Range 1.620 - 1.790
52wk Range 1.620 - 657.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Enveric Biosciences Inks Two Licensing Agreements With Restoration Biologics To Treat Joint Disease
Enveric's Akos Biosciences licensed its cannabinoid-COX-2 conjugate technology to Restoration Biologics for joint disease treatments, including osteoarthritis. 
Via Benzinga
Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease
From Enveric Biosciences
Via Business Wire

Performance

YTD
-98.02%
-98.02%
1 Month
-98.17%
-98.17%
3 Month
-98.36%
-98.36%
6 Month
-98.68%
-98.68%
1 Year
-99.10%
-99.10%

More News

Read More
Enveric Biosciences Announces Closing of $5 Million Public Offering
From Enveric Biosciences, Inc.
Via Business Wire
What's going on in today's session
Via Chartmill
Dow Edges Lower; Exxon Mobil Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Which stocks are gapping on Friday?
Via Chartmill
Nasdaq Jumps Over 150 Points; Apple Posts Upbeat Earnings
Via Benzinga
These stocks are moving in today's pre-market session
Via Chartmill
Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Enveric Biosciences Announces Pricing of $5 Million Public Offering
From Enveric Biosciences, Inc.
Via Business Wire
What's going on in today's after hours session
Via Chartmill
Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office
From Enveric Biosciences
Via Business Wire
Let's take a look at the stocks that are in motion in today's session.
Via Chartmill
Here are the top movers in Wednesday's session.
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds
From Enveric Biosciences
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results
Via Benzinga
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior
From Enveric Biosciences, Inc.
Via Business Wire
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders
Via Benzinga
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.